Previous Next
Adult pulmonary progenitor stem cells have been shown to regenerate lung epithelium in preclinical models. This clinical trial of P63+ progenitor cell transplantation was carried out on 68 patients with stage II to IV COPD. After isolation and culture for 3-5 weeks, P63+ progenitor cells were transplanted by bronchoscopy. No serious or grade 3-5 adverse events were reported. 24 weeks after transplantation, patients who received P63+ progenitor cells showed an improvement in their respiratory capacity and walking perimeter. Higher P63 expression was associated with better treatment efficacy.

Source(s) :
Yujia Wang et al. Autologous transplantation of P63+ lung progenitor cells for chronic obstructive pulmonary disease therapy. Sci Transl Med. 2024 Feb 14;16(734):eadi3360. ;

Last press reviews


HIV and Dual Therapy: a promising step towards maintaining viral suppression

The introduction of dual therapies in HIV treatment marks a significant ad...

L-arginine: a promising advance for reducing inflammatory and cardiac markers after coronary artery bypass surgery

Coronary artery bypass grafting (CABG) is a critical procedure to restore...

HIV and Innate Immunity: How Early Responses Shape the Evolution of Viral Reservoirs

HIV infection remains a significant challenge in the field of infectious d...